Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study

• DOI: 10.2337/dc22-0470
• Publication Date: 2022-08-16T08:53:28Z
• Authors: Bartłomiej Matejko; Anna Juza; Beata Kieć-Wilk; Katarzyna Cyranka; Sabina Krzyżowska; Xiaoxiao Chen; Ohad Cohen; Julien Da Silva; Maciej T. Malecki; Tomasz Klupa
• Keywords: Center (category theory)

The aim of this study was to evaluate the outcomes transitioning MiniMed 780G advanced hybrid closed-loop (AHCL) system in adult individuals with type 1 diabetes mellitus (T1DM) naive continuous subcutaneous insulin infusion (CSII) and glucose monitoring (CGM) technologies.This a two-center, randomized, controlled, parallel-group trial evaluation T1DM aged 26-60 years managed multiple daily injections (MDI) self-monitoring blood (BGM) HbA1c <10%.A total 41 participants were recruited randomized either AHCL (n = 20) or MDI+BGM 21) group, 37 (mean ± SD age 40.3 8.0 years, duration 17.3 12.1 BMI 25.1 3.1 kg/m2, 7.2 1.0%) completed study. Time spent levels target range increased from 69.3 12.3% at baseline 85.0 6.3% 3 months while remaining unchanged control group (treatment effect 21.5% [95% CI 15.7, 27.3]; P < 0.001). time below (<70 mg/dL) decreased 8.7 7.3% 2.1 1.7% remained -4.4% -7.4, -2.1]; Participants also had significant improvements -0.6% -0.9, -0.2]; 0.005) quality life (QoL) specific subscales compared group.People CSII CGM technologies initiating significantly safely improved their glycemic control, as well QoL psychological well-being.